<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Ruan C</submitter><funding>HwaMei Research Foundation of Ningbo No. 2 Hospital</funding><funding>Natural Science Foundation of Ningbo Municipality</funding><funding>Natural Science Foundation of Zhejiang Province</funding><funding>the Major Special Science and Technology Project of Ningbo City</funding><pagination>e70597</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11761428</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(3)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Hepatocellular carcinoma (HCC) is one of the most common and highly lethal cancers worldwide. RIO kinase 1 (RIOK1), a protein kinase/ATPase that plays a key role in regulating translation and ribosome assembly, is associated with a variety of malignant tumors. However, the role of RIOK1 in HCC remains largely unknown.&lt;h4>Methods&lt;/h4>Changes in RIOK1 expression in HCC and patient prognosis were evaluated using HCC tissues and public databases. The functional role of RIOK1 in HCC was analyzed by RTCA assay, clonogenic assay, and flow cytometry in vitro, and by mouse tumor xenograft model in vivo. Potential mechanism studies were performed using multi-omics analysis, public database screening, and qRT-PCR assay.&lt;h4>Results&lt;/h4>In this study, we found that RIOK1 was elevated</pubmed_abstract><journal>Cancer medicine</journal><pubmed_title>RIOK1: A Novel Oncogenic Driver in Hepatocellular Carcinoma.</pubmed_title><pmcid>PMC11761428</pmcid><funding_grant_id>LY19H160010</funding_grant_id><funding_grant_id>2023HMKY44</funding_grant_id><funding_grant_id>2021J314</funding_grant_id><funding_grant_id>2022HMKY59</funding_grant_id><funding_grant_id>2022Z128</funding_grant_id><pubmed_authors>Yang Y</pubmed_authors><pubmed_authors>Ruan C</pubmed_authors><pubmed_authors>Zhang S</pubmed_authors><pubmed_authors>Shen Y</pubmed_authors><pubmed_authors>Ru W</pubmed_authors><pubmed_authors>Shang T</pubmed_authors></additional><is_claimable>false</is_claimable><name>RIOK1: A Novel Oncogenic Driver in Hepatocellular Carcinoma.</name><description>&lt;h4>Background&lt;/h4>Hepatocellular carcinoma (HCC) is one of the most common and highly lethal cancers worldwide. RIO kinase 1 (RIOK1), a protein kinase/ATPase that plays a key role in regulating translation and ribosome assembly, is associated with a variety of malignant tumors. However, the role of RIOK1 in HCC remains largely unknown.&lt;h4>Methods&lt;/h4>Changes in RIOK1 expression in HCC and patient prognosis were evaluated using HCC tissues and public databases. The functional role of RIOK1 in HCC was analyzed by RTCA assay, clonogenic assay, and flow cytometry in vitro, and by mouse tumor xenograft model in vivo. Potential mechanism studies were performed using multi-omics analysis, public database screening, and qRT-PCR assay.&lt;h4>Results&lt;/h4>In this study, we found that RIOK1 was elevated</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Feb</publication><modification>2026-06-02T12:07:05.678Z</modification><creation>2025-04-04T13:12:14.602Z</creation></dates><accession>S-EPMC11761428</accession><cross_references><pubmed>39865406</pubmed><doi>10.1002/cam4.70597</doi></cross_references></HashMap>